Senior insider sale
Chief R&D Officer at NEKTAR THERAPEUTICS — senior position signals high conviction
$140.3K
3.36K shares
What this filing means
ZALEVSKY JONATHAN plans to sell 3.36K shares of NEKTAR THERAPEUTICS valued at approximately $140.3K. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 11/25/2025ACC: 0001959173-25-007274
Officer· Chief R&D Officer
Since Oct 2019
3.36K
Shares to sell
$140.3K
Approx. market value
1.16K
Acquired (3 months)
1
Planned
2 completed
Securities Acquired — Last 3 Months1
Restricted Stock Vesting
Compensation
11/21/2025
1.16KTotal acquired1.16K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
11/21/2025 | Restricted Stock Vesting Compensation | 1.16K | — |
| Total | 1.16K | ||
Planned & Completed Dispositions3
Completed
—Completed
Units to sell
1.72K
Market value
$57.7K
9/4/2025
—Completed
Units to sell
485.00
Market value
$14.6K
9/2/2025
Planned — Approximate Date
NASDAQPlanned
Units to sell
1.16K
Market value
$68.1K
11/25/2025
Total
Units
3.36K
Value
$140.3K
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
9/4/2025 | 1.72K | $57.7K | — | Completed |
9/2/2025 | 485.00 | $14.6K | — | Completed |
| Planned — Approximate Date | ||||
11/25/2025 | 1.16K | $68.1K | NASDAQ | Planned |
| Total | 3.36K | $140.3K | ||